Combination of <i>in vivo</i> phage therapy data with <i>in silico</i> model highlights key parameters for treatment efficacy
Raphaëlle Delattre(Centre National de la Recherche Scientifique), Laurent Debarbieux(Centre National de la Recherche Scientifique), Jean-Damien Ricard(Inserm), Baptiste Gaborieau(Délégation Paris 5), Rokhaya Kane(Centre National de la Recherche Scientifique), Jérémie Guedj(Inserm), Nicolas Dufour(Centre Hospitalier René-Dubos), Feyrouz Haddad(Centre National de la Recherche Scientifique), Thu-Thuy Nguyen(Inserm), Jérémy Seurat(Inserm)
Cited by 0
Related Papers
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
|Science|2020|382
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
|Pharmaceutical Research|2010|298
Prediction of strain level phage–host interactions across the Escherichia genus using only genomic information
|Nature Microbiology|2024|119